Questioning the aim of CML therapy in the era of Imatinib? Leukemia (2003) 17, 1199-1200. doi:10.1038/sj.leu.2402954
TO THE EDITOR
The idea of writing this comment came from a recent episode of the television series 'Law and Order', recently refferred to Stephen MacKinnon during a Plenary Session at the last ASCO Meeting. The episode depicted the trial of a father who shot an insurance executive for refusing to authorize the use of Imatinib for his daughter. Dr McKinnon concluded his talk saying that cost and availability of this novel targeted treatment is clearly going to pose serious problems. This episode confirms the great dilemma on the treatment of chronic myelogenous leukemia (CML) on the one hand and on the importance of media on the other. Imatinib could be considered the standard first-line therapy for patients with CML, 1 even if long-term survival and long-term toxicity remain unknown. Unfortunately, the International Randomized trial IFN-a/Ara-C vs Imatinib is still at 19 months and no firm conclusion may be drawn on blastic evolution and survival, with the exception of major cytogenetic remission already in favor of Imatinib. In the meantime, many studies involving Imatinib combined with Peg-IFN or lowdose ARA-C started many months ago, but the results of the aboverandomized trial are not yet available.
Two of the most convincing advantages of Imatinib were the facility of drug administration and the apparent absence of important side effects. The media amplified these facts and the patients almost always preferred to be treated with Imatinib instead of other transplantation or nontransplantation procedures. Also, the recent randomized trial comparing Imatinib to IFN-a/Ara-C demonstrated that very few patients abandoned Imatinib while over 70% of patients refused to continue IFN+Ara-C. By adding to Imatinib other drugs with different toxicity levels, we cannot be sure of offering a real benefit to our patients, but surely we will increase the toxicity! At the end of the day, I feel that it ought to be emphasized that facts say that the only cure for CML is still allogeneic transplantation. How feasible this is for many patients may be a function of finding a match. We need to reflect on the aim of CML therapy in the era of Imatinib. If the aim is the cure, defined as molecularnegative status after treatment, allogeneic transplantation has successfully provided that. The data on PCR status after IFN-a and Imatinib indicate that only a minority of patients reach PCR negativity, meaning that in cytogenetic remitters also, almost all patients still have minimal residual disease.
Since the problem with allogeneic transplantation is the mortality (30-40% with MUD and about 15-25% for patients with identical sibling donors), a good idea could be to start treatment of newly diagnosed patients with Imatinib. If the patients respond to Imatinib, this treatment should be continued and only high-risk Sokal/Euro patients should receive allogeneic transplantation if they have an HLA-identical donor. If the patients did not respond to Imatinib, conventional therapy, including allogeneic transplantation, should be given.
An alternative and more feasible approach for intermediate highrisk categories could be the protocol as sketched below, proposed originally by our group, and accepted by other South Italian teams. This protocol should be applied to patients for whom an allograft seems inappropriate by virtue of age, poor medical fitness, or lack of donor ( Figure 1) . All patients will receive Imatinib. After 6 months of Imatinib therapy, if the patient achieves complete hematologic remission (CHR)7complete cytogenetic remission (CCyR), G-CSF at 10 mcg/kg daily dose will be started and for 3-4 days in order to collect peripheral blood 2 Â 10 6 /kg hematopoietic progenitor cells (HPC). These cells will be studied for cytogenetics and BCR-ABL/ ABL ratio and cryopreserved; in the meantime, the patient resumes Imatinib therapy until disease progression. In that phase, high-dose chemotherapy (eg busulfan) followed by previously collected Ph negative or predominantly Ph-negative HPC, will be given. After engraftment, the patient will be 'maintained' with IFN-a, since the progression occurred on Imatinib. If, on the contrary, the patient achieves CHR but not CCyR, we can stop Imatinib, start in vivo mobilization chemotherapy with mini-ICE+G-CSF, and collect HPC which can be used as 'rescue' after high-dose busulfan.
2 After engraftment, IFN-a will be offered to the patient. Our experience with five patients mobilized in the above conditions showed in three of them an excellent quality of the collected cells in terms of CD34+ cells (42 Â 10 6 /Kg), with a content of leukemic cells lower than those found in the bone marrow as measured by RT-PCR for BCR-ABL transcripts.
As recently stated, Imatinib has disclosed new intriguing possibilities but few would claim that it actually cures CML. [3] [4] [5] [6] We do not know if this drug blocks the proliferative advantage of Ph-positive cells 7 or whether it indeed leads to the demise of all Imatinib-sensitive cells. 8 The difference between Dr Luzzatto's and our opinion is that we consider it more useful to employ an intensified approach consisting of Imatinib and high-dose therapy with rescue with the best collected cells instead of conventional therapy (IFN-a, Ara-C, etc) combined with Imatinib as the possible pharmacological cure. Since no patient autografted in early-chronic phase by our team died of transplanted-related causes, 2 the combined approach (Imatinib-Autografting) could represent an important future perspective for patients who have adverse prognostic characteristics.
